Literature DB >> 10617303

Antimetastatic effect of desmopressin in a mouse mammary tumor model.

D F Alonso1, G Skilton, E F Farías, E Bal de Kier Joffé, D E Gomez.   

Abstract

We have investigated the effects of desmopressin (DDAVP), a synthetic analog of the natural hormone vasopressin, on experimental lung colonization of mammary tumor cells using a syngeneic BALB/c mouse model. Coinjection of DDAVP (1-2 microg/kg body weight) at the time of i.v. inoculation of F3II carcinoma cells or LM3 adenocarcinoma cells significantly inhibited the formation of experimental lung metastases. In both cases, the number of pulmonary nodules was reduced about 70%. Inhibition of metastasis was also obtained with i.v. administration of DDAVP 24 h after tumor cell inoculation. Interestingly, the inhibition of lung metastasis was not due to direct cytotoxic effects of DDAVP on mammary tumor cells. The in vitro formation of multicellular aggregates in the presence of citrated plasma from control and DDAVP-treated mice was also examined. Control plasma rapidly induced a significant tumor cell aggregation. In contrast, in the presence of plasma from DDAVP-treated mice, tumor cells remained as a single cell suspension. DDAVP may help to dissolve the protective fibrin shield of circulating tumor cells. Our data suggest, for the first time, that adjuvant DDAVP therapy may impair successful implantation of circulating mammary tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10617303     DOI: 10.1023/a:1006291607871

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

Review 2.  Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin.

Authors:  D F Alonso; G V Ripoll; J Garona; N B Iannucci; D E Gomez
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

3.  The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.

Authors:  Juan Garona; Marina Pifano; Ulises D Orlando; Maria B Pastrian; Nancy B Iannucci; Hugo H Ortega; Ernesto J Podesta; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Int J Oncol       Date:  2015-04-03       Impact factor: 5.650

4.  Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.

Authors:  Giselle V Ripoll; Juan Garona; Marina Pifano; Hernan G Farina; Daniel E Gomez; Daniel F Alonso
Journal:  Breast Cancer Res Treat       Date:  2013-11       Impact factor: 4.872

5.  Antiproliferative Effects of Oxytocin and Desmopressin on Canine Mammary Cancer Cells.

Authors:  Micaela Andrea Benavente; Carolina Paula Bianchi; Fernanda Imperiale; Marcelo Alfredo Aba
Journal:  Front Vet Sci       Date:  2016-12-26

Review 6.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07

7.  Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer.

Authors:  Juan Garona; Natasha T Sobol; Marina Pifano; Valeria I Segatori; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.679

8.  Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.

Authors:  Sonali Sinha; Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Vijayakumar R Kakade; Maura O' Neil; Robert H Weiss; Jonathan Enders; James P Calvet; Sufi M Thomas; Reena Rao
Journal:  Oncogene       Date:  2019-10-15       Impact factor: 9.867

9.  A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Authors:  Ruth S Weinberg; Marcelo O Grecco; Gimena S Ferro; Debora J Seigelshifer; Nancy V Perroni; Francisco J Terrier; Analía Sánchez-Luceros; Esteban Maronna; Ricardo Sánchez-Marull; Isabel Frahm; Marcelo D Guthmann; Daniela Di Leo; Eduardo Spitzer; Graciela N Ciccia; Juan Garona; Marina Pifano; Ana V Torbidoni; Daniel E Gomez; Giselle V Ripoll; Roberto E Gomez; Ignacio A Demarco; Daniel F Alonso
Journal:  Springerplus       Date:  2015-08-19

Review 10.  Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.

Authors:  Mladena Glavaš; Agata Gitlin-Domagalska; Dawid Dębowski; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.